drugset
Drugs / CT-996
last change Nov 2025 re-read 3 minutes ago

CT-996

Developed for
obesity disorder · type 2 diabetes mellitus
Investigated by
Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. · Hoffmann-La Roche

Trials 1

today NCT05814107 · Ph 1
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05814107 May 2023 → Nov 2025 obesity disorder, type 2 diabetes mellitus Carmot Therapeutics, Inc. Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2024-07-17 Hoffmann-La Roche [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity roche.com ↗
2024-07-16 Genentech, Inc. Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity gene.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CT-996 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05814107 ↗